CN109172650A - 一种防治小鹅瘟的中药组合物及其制备方法和应用 - Google Patents
一种防治小鹅瘟的中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN109172650A CN109172650A CN201811393727.5A CN201811393727A CN109172650A CN 109172650 A CN109172650 A CN 109172650A CN 201811393727 A CN201811393727 A CN 201811393727A CN 109172650 A CN109172650 A CN 109172650A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- chinese medicine
- gosling plague
- filtering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 68
- 241000607479 Yersinia pestis Species 0.000 title claims abstract description 41
- 206010035148 Plague Diseases 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 241001183967 Isodon Species 0.000 claims abstract description 32
- 241000510678 Falcaria vulgaris Species 0.000 claims abstract description 31
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 27
- 241000282320 Panthera leo Species 0.000 claims abstract description 27
- 230000002265 prevention Effects 0.000 claims abstract description 22
- 241000628997 Flos Species 0.000 claims abstract description 20
- 241000411851 herbal medicine Species 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 178
- 235000019441 ethanol Nutrition 0.000 claims description 96
- 239000012530 fluid Substances 0.000 claims description 44
- 239000000706 filtrate Substances 0.000 claims description 36
- 238000001914 filtration Methods 0.000 claims description 34
- 238000004064 recycling Methods 0.000 claims description 30
- 229940079593 drug Drugs 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000001816 cooling Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 10
- -1 filtering Substances 0.000 claims description 7
- 229940100688 oral solution Drugs 0.000 claims description 7
- 241001517118 Goose parvovirus Species 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract 1
- 241000272814 Anser sp. Species 0.000 description 33
- 230000001376 precipitating effect Effects 0.000 description 20
- 210000001161 mammalian embryo Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 229920001817 Agar Polymers 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 241000700605 Viruses Species 0.000 description 5
- 231100000668 minimum lethal dose Toxicity 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 239000008272 agar Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 3
- 229960003805 amantadine Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000003837 chick embryo Anatomy 0.000 description 3
- 238000012817 gel-diffusion technique Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 241000234435 Lilium Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000001779 embryotoxic effect Effects 0.000 description 2
- 231100000238 embryotoxicity Toxicity 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004080 punching Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- MFRCZYUUKMFJQJ-UHFFFAOYSA-N 1,4-dioxane-2,5-dione;1,3-dioxan-2-one Chemical compound O=C1OCCCO1.O=C1COC(=O)CO1 MFRCZYUUKMFJQJ-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000000197 Acute Cholecystitis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 101100279436 Caenorhabditis elegans egg-2 gene Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000205571 Caulophyllum Species 0.000 description 1
- 206010008614 Cholecystitis acute Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 241001225982 Isodon walkeri Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241001453894 Lindsaeaceae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241001453732 Odontosoria chinensis Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241001552676 Trollius asiaticus Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 206010025226 lymphangitis Diseases 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种防治小鹅瘟的中药组合物及其制备方法和应用。该组合物由大叶金花草14~42重量份,四方草15~45重量份,狮子草6~18重量份,宽瓣金莲花3~9重量份的原料药组成。该中药组合物用于制备防治小鹅瘟的中兽药物,见效快、副作用小,安全方便。
Description
技术领域
本发明属于中兽药制药领域,涉及一种防治小鹅瘟的中药组合物。本发明还涉及该中药组合物的制备方法及该中药组合物在制备防治小鹅瘟的中兽药中的应用。
背景技术
小鹅瘟是由鹅细小病毒引起的一种传播较快、死亡率高、高度接触性败血性传染病。主要危害1月龄以内的雏鹅,是严重危害我国养鹅业发展的重要传染病之一。目前,预防小鹅瘟的主要措施是,母鹅在开产前1月注射小鹅瘟疫苗,或雏鹅在出壳后3~5日龄内注射小鹅瘟血清或卵黄抗体,而一旦发病后,治疗小鹅瘟的药物较少,即使有个别品种能够防治小鹅瘟,但却存在着容易复发和不能根治的弊病。而且中药的剂型是散剂较多,药物释放较慢,生物利用度低,临床效果不是很好;而各种抗病毒西药如利巴韦林、金刚烷胺等,农业农村部已经禁止畜禽使用。
因此研发一种防治小鹅瘟的无药物残留、无耐药性产生、生物利用度高、临床效果显著的有效药物是急待解决的新课题。
发明内容
本发明的目的在于提供一种防治小鹅瘟的中药组合物。
本发明另一个目的是提供上述防治小鹅瘟中药组合物的制备方法。
本发明还有一个目的是提供上述防治小鹅瘟的中药组合物在中兽药物中的应用。
本发明的目的是通过下列技术措施来实施的:
一种防治小鹅瘟的中药组合物,该组合物由下列重量份的组分制成:大叶金花草14~42重量份,四方草15~45重量份,狮子草6~18重量份,宽瓣金莲花3~9重量份。
上述组合物优选由下列重量份的组分组成:
大叶金花草16~22重量份,四方草15~20重量份,狮子草6~10重量份,宽瓣金莲花4~7重量份。
上述组合物进一步优选由下列重量份的组分组成:
大叶金花草16~18重量份,四方草17~20重量份,狮子草8~10重量份,宽瓣金莲花5~7重量份。
该组合物与药学可接受的辅料制成制剂,优选制剂为口服液。
上述防治小鹅瘟的中药组合物是通过下列步骤制备得到的:
将大叶金花草、四方草、狮子草、宽瓣金莲花混合,加水浸泡24~30小时后煎煮2~3次,每次煮沸后维持0.5~1小时,合并煎液并浓缩至稠状,加重量百分比浓度为95%乙醇调至醇浓度为60%~70%,充分搅拌混匀,沉淀,过滤,滤液回收乙醇,回收乙醇后的药液再加95%乙醇调至醇浓度为75%~80%,搅匀,沉淀,过滤,滤液回收乙醇再浓缩至无醇味,药液加水冷藏,沉淀,过滤,滤液浓缩。
上述防治小鹅瘟的中药口服液是通过下列步骤得到的:
将大叶金花草、四方草、狮子草、宽瓣金莲花混合,加水浸泡24~30小时后煎煮2~3次,每次煮沸后维持0.5~1小时,合并煎液并浓缩至稠状,加重量百分比浓度为95%乙醇调至醇浓度为60%~70%,充分搅拌混匀,沉淀,过滤,滤液回收乙醇,回收乙醇后的药液再加95%乙醇调至醇浓度为75%~80%,搅匀,沉淀,过滤,滤液回收乙醇再浓缩至无醇味,药液加水冷藏,沉淀,过滤,滤液浓缩,得浓度为每mL含1~2g生药量的药液,制成口服液。
该中药组合物在防治小鹅瘟传染病中应用,具有显著疗效,可应用于制备防治小鹅瘟的中兽药物。
本发明药物防治小鹅瘟近万例,均取得较好疗效,一般治疗3天后停止死亡,4~5天痊愈,见效快,治愈后一般不复发,表明本发明药物有甚高疗效,且副作用小,安全方便。
本发明的有益效果:本发明吸取中兽医学精髓;大叶金花草(鳞始蕨科植物)Sphenomeris chinensis(L)Maxon.具有清热解毒、利湿,止血功效。主治感冒发热,咳嗽,咽喉肿痛,肠炎,肝炎,痈疮肿毒,狂犬、毒蛇咬伤,皮肤湿疹,吐血,尿血,便血。四方草(唇形科植物)Rabdosia stracheyi(Benth.ex llook.f.)Hara.具有清热利湿,活血散瘀功效。主治急性黄疸型肝炎,急性胆囊炎,水肿,中暑,跌打瘀痛,乳疮。狮子草(唇形科植物)Rabdosiayuennanensis(Hand-Mazz)Hara..具有祛风利湿、活血通络,解毒消毒功效。主治感冒,风湿骨痛,食积,痢疾,黄疸,疮疡,疥癣,狂犬咬伤。宽瓣金莲花(毛莨科植物)Trolliusasiaticus L.具有清热解毒,消毒,明目功效。主治感冒发热,咽喉肿痛,牙龈肿痛,目赤肿痛,疔疮肿毒,急性***炎。本发明组合以大叶金花草为君药,4种药物配伍,达到标本兼治的目的,对小鹅瘟有很好的防治作用。
下面就本发明的效果进一步说明本发明的疗效。
一、本发明体外抗小鹅瘟病毒试验研究
1、药品:本试验以本发明为试验药品(按实施例1制备得到);以0.2毫克/毫升的金刚烷胺为西药对照。
2、小鹅瘟病毒毒株、小鹅瘟阳性血清由扬州大学提供。
3、非免鹅胚:购自扬州市仪征鹅场。
4、琼脂平板:取1g优质琼脂加到100mLpH7.8的8%氯化钠溶液中,加热溶解后,加入1mL1%硫柳汞溶液,混匀后倾倒平板,厚约3mm,冷却后按梅花形打孔,中央孔和外周孔孔径3mm,孔距4mm,封底后备用。琼脂平板由江苏农牧科技职业学院预防兽医教研室配制。
5、试验分组:孵化13日龄鹅胚40个,随机分4组,具体分组情况见表1。
表1实验分组情况
7、试验方法:
(1)病毒复壮,测定最小致死量将不同浓度病毒稀释液接种非免鹅胚,弃去48小时内死胚,收取9天内活胚和2~9天死胚尿囊液,再将尿囊液稀释不同倍数,接种非免鹅胚,得出胚胎最小致死量(即尿囊液最小致死量的稀释度为1∶200)。正式接种试验的尿囊液为1∶200,每个鹅胚接种0.2毫升。
(2)药物毒性试验中药原药液用生理盐水作倍比稀释,将中药原液及不同浓度的药液分别接种于4枚12日龄鹅胚尿囊腔中,每只0.2毫升,置37.8℃温箱孵育9天,每天观察存活情况,鹅胚全部存活的最高药液浓度为正式试验起始浓度,同时设生理盐水对照组,药物对鹅胚毒性试验结果见表2。
表2中药对鹅胚毒性实验结果
★分母为接种胚数,分子为存活胚数。
(3)具体方法
试验Ⅰ组 每个鹅胚尿囊腔同时接种中药0.2毫升,病毒0.2毫升。
试验Ⅱ组 每个鸡胚尿囊腔同时接种西药0.2毫升,病毒0.2毫升。
感染对照组 每个鸡胚尿囊腔同时接种生理盐水0.2毫升,病毒0.2毫升。
空白对照组 不接种病毒,不给药。
上述鸡胚在37.8℃温箱中继续孵化,每天照蛋2~3次,充去48小时内死胎,收取9天内活胚和2~9天死胚的尿囊液,低温保存备用。以琼脂扩散试验检测鹅胚尿囊液的病毒繁殖情况。
(4)琼脂扩散试验方法将制备好的琼脂板按梅花图打孔封底,孔径及孔距均为3毫米。中央孔加阳性血清,周围孔加接种孵育的鸡胚尿囊液,中央孔与抗原孔之间形成清晰沉淀线判定为阳性(++)。中央孔与抗原孔之间形成的不清晰沉淀线判定为弱阳性(+),中央孔与抗原孔之间无沉淀线为阴性(-)。
中药对小鹅瘟病毒增殖的影响,用琼脂扩散试验测定,结果见表3。
表3中药对小鹅瘟病毒增殖的抑制作用测定结果
与感染组比较:★表示P<0.05,★★表示P<0.01。
二、本发明对实验性小鹅瘟的治疗试验
1、试验动物购种鹅未接种小鹅瘟疫苗种蛋孵化的1日龄雏鹅两批,分别饲养至10日龄。第1批50只,用于病毒致死量测定。第2批180只,将鹅分为6个组,每组30只,即中药预防组与治疗组,西药预防组与治疗组,感染对照组,空白对照组。
2、小鹅瘟毒株由扬州大学提供。
3、试验方法:
(1)先测定尿囊液最小致死量,通过测定,尿囊液的最小致死量为150倍稀释,每只鹅口服0.4毫升。
(2)接种空白对照组不接种尿囊液,不用药,其余5个组的鹅在同一时间里,每只鹅口服稀释后的尿囊液0.4毫升。
(3)用药时间发明预防组在接种尿囊液的同时,开始用本发明中药口服(按实施例4制备得到),每只鹅每次1毫升,每天用药2次,连用5天。发明治疗组在接种尿囊液4天后(出现症状)用药,每只鹅每次1毫升,每天用药2次,连用5天。西药预防组在接种尿囊液的同时,开始用0.2毫克/毫升的金刚烷胺口服,每只鹅每次1毫升,每日2次,连用5天。西药治疗组在接种尿囊液4天后(出现症状)用药,用0.2毫克/毫升的金刚烷胺口服,每只鸡每次1毫升,每天2次,连用5天,感染对照组的鹅只接种尿囊液,不用任何药物,结果见表4。
本发明的积极效果是一种纯中药制剂,副作用小,使用安全方便,吸收快。对小鹅瘟的治愈率在90%左右,避免了兽药残留和社会公害的发生。
表4小鹅瘟预防与治疗结果
三、小鹅瘟的临床治疗观察
小鹅瘟是雏鹅的一种烈性传染病,雏鹅一旦感染,可在鹅群中迅速传播,且病死率高,使养殖户遭受严重的经济损失。用5组药物:本发明组(按实施例1制备得到)、大叶金花草组、四方草组、四方草+狮子草组、宽瓣金莲花+四方草+狮子草组,在江苏仪征鹅场对发病鹅进行中药治疗,每只鹅每次1毫升口服,每天2次,连用5天,共治疗病鹅四千多只。
本发明组(按实施例1制备得到);
大叶金花草组:取大叶金花草46g,将大叶金花草药材加其重量5倍的水浸泡24小时,浸泡24小时后煎煮3次,每次煮沸后维持0.5小时以上,合并煎液并浓缩至稠状,加重量百分比浓度为95%的乙醇调至乙醇浓度60%,充分搅拌混匀,沉淀48小时以上,过滤,滤液回收乙醇,回收乙醇后的药液再加95%乙醇调至醇浓度75%,搅匀沉淀48小时,过滤,滤液回收乙醇,再浓缩至无醇味,药液加4倍量水冷藏沉淀48小时,过滤,滤液浓缩,得浓度为为每mL含生药1.5g的药液。
四方草组:取四方草46g,将四方草药材加其重量5倍的水浸泡24小时,浸泡24小时后煎煮3次,每次煮沸后维持0.5小时以上,合并煎液并浓缩至稠状,加重量百分比浓度为95%的乙醇调至乙醇浓度60%,充分搅拌混匀,沉淀48小时以上,过滤,滤液回收乙醇,回收乙醇后的药液再加95%乙醇调至醇浓度75%,搅匀沉淀48小时,过滤,滤液回收乙醇,再浓缩至无醇味,药液加4倍量水冷藏沉淀48小时,过滤,滤液浓缩,得浓度为每mL含生药1.5g的药液。
四方草+狮子草组:取四方草30g,狮子草16g,添加2味药材总重量5倍的水,浸泡24小时后煎煮3次,每次煮沸后维持0.5小时以上,合并煎液并浓缩至稠状,加重量百分比浓度为95%的乙醇调至乙醇浓度60%,充分搅拌混匀,沉淀48小时以上,过滤,滤液回收乙醇,回收乙醇后的药液再加95%乙醇调至醇浓度75%,搅匀沉淀48小时,过滤,滤液回收乙醇,再浓缩至无醇味,药液加4倍量水冷藏沉淀48小时,过滤,滤液浓缩,得浓度为每mL含生药1.5g的药液。
四方草+狮子草组+宽瓣金莲花:取大四方草30g,狮子草10g,宽瓣金莲花6g,按照以下方法制备:
将四方草、狮子草、宽瓣金莲花加3味药材总重量5倍的水浸泡24小时后,煎煮3次,每次煮沸后维持0.5小时以上,合并煎液并浓缩至稠状,加重量百分比浓度为95%的乙醇调至乙醇浓度60%,充分搅拌混匀,沉淀48小时以上,过滤,滤液回收乙醇,回收乙醇后的药液再加95%乙醇调至醇浓度75%,搅匀沉淀48小时,过滤,滤液回收乙醇,再浓缩至无醇味,药液加4倍量水冷藏沉淀48小时,过滤,滤液浓缩,得浓度为每mL含生药1.5g的药液。对小鹅瘟的疗效结果见表5。
表5小鹅瘟临床疗效结果
五、安全性试验
取ICR小鼠30只,体重在25~30克,按体重随机分成5组,每组6只,雌雄各半,口服给药(按实施例2制备得到),给药量分别为0.2毫升/只、0.4毫升/只、0.6毫升/只和0.8毫升/只,每天口服2次,连续给药5天,停药后连续观察20天。对照组自由饮水。结果所有小鼠健存,其活动、饮食、毛发、***物未发现异常,未见毒性反应。对小鼠口腔和破损皮肤进行刺激性试验,未见有刺激性反应和其它不良反应。
具体实施方式:
下面结合具体实施例对本发明作进一步的描述:
实施例1:
组方:大叶金花草16g,四方草17g,狮子草8g,宽瓣金莲花5g
具体制备过程如下:
将大叶金花草、四方草、狮子草、宽瓣金莲花药材加总重量5倍的水浸泡24小时后煎煮3次,每次煮沸后维持0.5小时以上,合并煎液并浓缩至稠状,加重量百分比浓度为95%的乙醇调至乙醇浓度60%,充分搅拌混匀,沉淀48小时以上,过滤,滤液回收乙醇,回收乙醇后的药液再加95%乙醇调至醇浓度75%,搅匀沉淀48小时,过滤,滤液回收乙醇,再浓缩至无醇味,药液加4倍量水冷藏沉淀48小时,过滤,滤液浓缩,得浓度为每mL含生药1.5g的药液,制成口服液,分装,灭菌即得。
实施例2:
组方:大叶金花草14g,四方草15g,狮子草6g,宽瓣金莲花3g
具体制备过程如下:
将大叶金花草、四方草、狮子草、宽瓣金莲花药材加总重量5倍的水浸泡浸泡24小时后后煎煮3次,每次煮沸后维持0.5小时以上,合并煎液并浓缩至稠状,加重量百分比浓度为95%的乙醇调至乙醇浓度60%,充分搅拌混匀,沉淀48小时以上,过滤,滤液回收乙醇,回收乙醇后的药液再加95%乙醇调至醇浓度75%,搅匀沉淀48小时,过滤,滤液回收乙醇,再浓缩至无醇味,药液加4倍量水冷藏沉淀48小时,过滤,滤液浓缩,得浓度为每mL含生药1g的药液,制成口服液,分装,灭菌即得。
实施例3:
组方:大叶金花草28g,四方草32g,狮子草13g,宽瓣金莲花5g
具体制备过程如下:
将大叶金花草、四方草、狮子草、宽瓣金莲花药材加总重量6倍的水浸泡30小时后煎煮3次,每次煮沸后维持1小时,合并煎液并浓缩至稠状,加重量百分比浓度为95%乙醇调至乙醇浓度65%,充分搅拌混匀,沉淀60小时,过滤,滤液回收乙醇。回收乙醇后的药液再加95%乙醇调至醇浓度80%,搅匀沉淀48小时,过滤,滤液回收乙醇,再浓缩至无醇味,药液加2倍量水冷藏沉淀24小时,过滤,滤液浓缩,得浓度为每mL含生药2g的药液,制成口服液,分装,灭菌即得。
实施例4:
组方:大叶金花草18g,四方草19g,狮子草10g,宽瓣金莲花7g
具体制备过程如下:
将大叶金花草、四方草、狮子草、宽瓣金莲花药材加总重量7倍的水浸泡27小时后,煎煮3次,每次煮沸后维持1小时,合并煎液并浓缩至稠状,加重量百分比浓度为95%乙醇调至乙醇浓度70%,充分搅拌混匀,沉淀48小时,过滤,滤液回收乙醇。回收乙醇后的药液再加95%乙醇调至醇浓度80%,搅匀沉淀48小时,过滤,滤液回收乙醇,再浓缩至无醇味,药液加3倍量水冷藏沉淀24小时,过滤,滤液浓缩,得浓度为每mL含生药1.5g的浓度,制成口服液,分装,灭菌即得。
Claims (8)
1.一种防治小鹅瘟的中药组合物,其特征在于该组合物由以下重量份的组分制成:大叶金花草14~42重量份,四方草15~45重量份,狮子草6~18重量份,宽瓣金莲花3~9重量份。
2.根据权利要求1所述的防治小鹅瘟的中药组合物,其特征在于该组合物由以下重量份的组分制成:大叶金花草16~22重量份,四方草15~20重量份,狮子草6~10重量份,宽瓣金莲花4~7重量份。
3.根据权利要求1所述的防治小鹅瘟的中药组合物,其特征在于该组合物由以下重量份的组分制成:大叶金花草16~18重量份,四方草17~20重量份,狮子草8~10重量份,宽瓣金莲花5~7重量份。
4.根据权利要求1、2或3所述的防治小鹅瘟病毒的中药组合物,其特征在于该组合物与药学可接受的辅料制成制剂。
5.根据权利要求4所述的防治小鹅瘟的中药组合物,其特征在于所述的制剂为口服液。
6.一种权利要求1、2或3所述的防治小鹅瘟的中药组合物的制备方法,其特征在于该方法包括以下步骤:
将大叶金花草、四方草、狮子草、宽瓣金莲花混合,加水浸泡24~30小时后煎煮2~3次,每次煮沸后维持0.5~1小时,合并煎液并浓缩至稠状,加重量百分比浓度为95%乙醇调至醇浓度为60%~70%,充分搅拌混匀,沉淀,过滤,滤液回收乙醇,回收乙醇后的药液再加95%乙醇调至醇浓度为75%~80%,搅匀,沉淀,过滤,滤液回收乙醇再浓缩至无醇味,药液加水冷藏,沉淀,过滤,滤液浓缩。
7.一种权利要求5所述的防治小鹅瘟的中药口服液的制备方法,其特征在于该方法包括以下步骤:
将大叶金花草、四方草、狮子草、宽瓣金莲花,加水浸泡24~30小时后,煎煮2~3次,每次煮沸后维持0.5~1小时,煎液合并后浓缩至稠状,加重量百分比浓度为95%的乙醇调至醇浓度60%~70%,充分搅匀,沉淀,过滤,滤液回收乙醇,回收乙醇后的药液再加重量百分比浓度为95%乙醇调至醇浓度为75%~80%,搅匀,沉淀,过滤,滤液回收乙醇后再浓缩至无醇味,药液加水冷藏,沉淀,过滤,滤液浓缩,得浓度为每mL含生药1-2g的药液,即得口服液。
8.权利要求1、2或3所述的防治小鹅瘟病毒中药组合物在制备防治小鹅瘟的中兽药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811393727.5A CN109172650A (zh) | 2018-11-21 | 2018-11-21 | 一种防治小鹅瘟的中药组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811393727.5A CN109172650A (zh) | 2018-11-21 | 2018-11-21 | 一种防治小鹅瘟的中药组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109172650A true CN109172650A (zh) | 2019-01-11 |
Family
ID=64940459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811393727.5A Withdrawn CN109172650A (zh) | 2018-11-21 | 2018-11-21 | 一种防治小鹅瘟的中药组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109172650A (zh) |
-
2018
- 2018-11-21 CN CN201811393727.5A patent/CN109172650A/zh not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101023997A (zh) | 抗禽流感病毒的中药及其制作方法 | |
CN103006792A (zh) | 一种防治畜禽肠道疾病的中兽药及其制备方法与饲料 | |
CN101780153B (zh) | 一种猪用中药组合物及其制备方法和应用 | |
CN102038100A (zh) | 用于预防和治疗猪瘟的饲料添加剂 | |
CN100586454C (zh) | 一种禽用中药组合物及其制备方法和应用 | |
CN104435023B (zh) | 一种中药提取物及其应用 | |
CN103768157A (zh) | 一种兽用抗病毒中药紫芪泡腾颗粒药物及其制备方法 | |
CN102670694A (zh) | 一种治疗猪伪狂犬病的中药组合物及其制备方法和应用 | |
CN109172650A (zh) | 一种防治小鹅瘟的中药组合物及其制备方法和应用 | |
CN109498701A (zh) | 一种防治鹅副粘病毒的中药组合物及其制备方法和应用 | |
CN111569059B (zh) | 一种禽类用抗原-抗体复相疫苗及制备方法 | |
CN105726742B (zh) | 一种抗鸡新城疫病毒病和禽流感的中兽药及其制备方法 | |
CN107929685A (zh) | 一种治疗羔羊痢疾的组合物及其制备方法 | |
CN107375866A (zh) | 一种中药组合物在制备用于仔猪保健促生长的药物中的用途 | |
CN103784685B (zh) | 治疗畜禽病毒性传染病的中药组合物及其制备方法和应用 | |
CN109045127A (zh) | 一种药物组合物在防治鸡传染性支气管炎的应用 | |
CN108653455A (zh) | 一种防治鹅副粘病毒病的中药组合物及其制备方法和应用 | |
CN107854526A (zh) | 一种治疗鸡大肠杆菌病的中药组合物及其制备方法和应用 | |
CN106361987A (zh) | 一种猪用中药组合物及其制备方法和应用 | |
CN114246940B (zh) | 含苦参功劳颗粒的药物组合物的应用 | |
CN116036188B (zh) | 防治鸡球虫病的中药组合物及其制备方法与应用 | |
CN102309643A (zh) | 一种用于治疗鸡球虫病的中药组合物 | |
CN109674860A (zh) | 一种治疗犬传染性肝炎的中药组合物及其制备方法和应用 | |
CN104644803A (zh) | 一种禽用抗球虫中药口服液的制备方法 | |
CN106924448A (zh) | 治疗风热感冒的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190111 |